|
|
|
| Changes of drug resistance of Pseudomonas aeruginosa and rationality analysis of antibiotics in respiratory department of our hospital |
| WU Along HUANG Jian XU Bingfa |
| Department of Pharmacy, the Third Hospital Affiliated to Anhui Medical University, Anhui Province, Hefei 230061, China |
|
|
|
Abstract Objective To investigate the drug resistance of Pseudomonas aeruginosa (PA) in respiratory department and the choice of antibiotics in patients to provide evidence for rational use of antibiotics. Methods The trend of drug resistance of PA in the Third Affiliated Hospital of Anhui Medical University (hereinafter referred to as “our hospital”) from 2013 to 2020 was retrospectively analyzed, and the antimicrobial resistance rate of patients with PA infection in respiratory department was retrospectively analyzed. According to the drug susceptibility results, the included patients were divided into carbapenem-resistant pseudomonas aeruginosa (CRPA) group (31 cases) and non-carbapenem-resistant pseudomonas aeruginosa (NCRPA) group (127 cases). The rationality and outcome of the choice of antibiotics in the two groups were evaluated. Results The drug resistance of PA to ceftazidime, cefepime, piperacillin-tazobactam, and imipenem were showed a trend of first decline and then increased, and the drug resistance rate was slightly higher than that of the whole hospital. The mortality rate in the CRPA group was higher than that in the NCRPA group, while the rational rate of antibiotic selection was lower than that in the NCRPA group, with statistically significant differences (P ＜ 0.05). The unreasonable situations were that the combination of antibiotics was not used according to the drug susceptibility results, and the PA-sensitive antibiotics were not selected. Conclusion After 2015, the PA drug resistance rate has been increasing year by year. Paying attention to patients with high risk factors of drug resistance and selecting antimicrobial drugs based on drug susceptibility results can guide the treatment of PA.
|
|
|
|
|
|
[1] 余建洪，李敏，何小平，等.2016—2018年某医院耐碳青霉烯类铜绿假单胞菌的耐药性及临床特征分析[J].安徽医药，2021，25（5）：931-934.
[2] Chamieh A，El-Hajj G，Zmerli O，et al. Carbapenem resistant organisms：a 9-year surveillance and trends at Saint George university medical center [J]. J Infect Public Health，2020，13（12）：2101-2106.
[3] Viasus D，Puerta-Alcalde P，Cardozo C，et al. Predictors of multidrug-resistant Pseudomonas aeruginosa in neutropenic patients with bloodstream infection [J]. Clin Microbiol Infect，2020，26（3）：345-350.
[4] 张新颖，韩颖，王雅妹，等.铜绿假单胞菌耐药性与抗菌药物使用强度相关性分析[J].河北大学学报（自然科学版），2021，41（2）：188-194.
[5] CLSI/ Clinical and Laboratory Standards Institute，Performance Standards for Antimicrobial Susceptibility Testing; twenty-first informational supplement [S]. M100-S26， 2016：62-64.
[6] 王明贵.广泛耐药革兰阴性菌感染的实验诊断、抗菌治疗及医院感染控制：中国专家共识[J].中国感染与化疗杂志，2017，17（1）：82-92.
[7] Grossman S，Soukarieh F，Richardson W，et al. Novel quinazolinone inhibitors of the Pseudomonas aeruginosa quorum sensing transcriptional regulator PqsR [J]. Eur J Med Chem，2020，208：112778.
[8] Le MN，Kayama S，Yoshikawa M，et al. Oral colonisation by antimicrobial-resistant Gram-negative bacteria among longterm care facility residents：prevalence，risk factors，and molecular epidemiology [J]. Antimicrob Resist Infect Control，2020，9（1）：45.
[9] 郑少微，李萍，张正良，等.2005—2017年中国CHINET常见革兰阴性菌对碳青霉烯类抗生素耐药的监测结果[J].临床急诊杂志，2019，20（1）：40-44.
[10] Hu FP. Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance，2005—2014 [J]. Chin J Infect Chemothe，2017，17（1）：93-99.
[11] Hu FP，Zhu DM，Wang F，et al. Report of CHINET antimicrobial resistance surveillance program in 2015 [J]. Chin J Infect Chemother，2016，16（6）：685-694.
[12] Hu FP，Guo Y，Zhu DM，et al. Antimicrobial resistance profile of clinical isolates in hospitals across China：report from the CHINET Surveillance Program，2017 [J]. Chin J Infect Chemother，2018，18（3）：241-251.
[13] 蒙光义，周丽娟，梁翠玲，等.铜绿假单胞菌耐药率与抗菌药物使用强度的相关性研究[J].中国医院药学杂志，2019，39（1）：87-91.
[14] 聂亚红，田可港，孙玉娟，等.医院铜绿假单胞菌的临床特征及危险因素分析[J].中国抗生素杂志，2021，46（6）：611-615.
[15] 杜晓露，周华，符一骐，等.铜绿假单胞菌血流感染患者细菌耐药性及预后影响因素分析[J].中国感染与化疗杂志，2020，20（2）：118-124.
[16] 熊玲玲，马琼，袁有华，等.铜绿假单胞菌血流感染57例的死亡危险因素分析[J].中国感染与化疗杂志，2021， 21（3）：254-257.
[17] 陈志辉，吴红梅，徐子琴，等.预测住院患者获得耐碳青霉烯类铜绿假单胞菌医院感染的列线图模型的构建[J].中华医院感染学杂志，2019，29（7）：966-970.
[18] Khaledi A，Weimann A，Schniederjans M，et al. Predicting antimicrobial resistance in Pseudomonas aeruginosa with machine learning-enabled molecular diagnostics [J]. EMBO Mol Med. 2020，12（3）：e10264.
[19] Ren Z，Zheng X，Yang H，et al. Human umbilical-cord mesenchymal stem cells inhibit bacterial growth and alleviate antibiotic resistance in neonatal imipenem-resistant Pseudomonas aeruginosa infection [J]. Innate Immun，2020，26（3）：215-221.
[20] Xu Y，Niu H，Hu T，et al. High Expression of Metallo-β-Lactamase Contributed to the Resistance to Carbapenem in Clinical Isolates of Pseudomonas aeruginosa from Baotou，China [J]. Infect Drug Resist，2020，13：35-43.
[21] 中华医学会呼吸病学分会感染学组.铜绿假单胞菌下呼吸道感染诊治专家共识[J].中华结核和呼吸杂志，2014， 37（1）：9-15.
[22] 徐丙发，周银娣，丁震，等.某院耐碳青霉烯类肠杆菌感染患者抗菌药物使用分析[J].中华医院感染学杂志，2019， 29（23）：3526-3529.
[23] Queenan AM，Bush K. Carbapenemases：the versatile beta-lactamases [J]. Clin Microbiol Rev，2007，20（3）：440-458.
[24] Wang X，Wang Q，Cao B，et al. Impact of Combination Therapy vs Monotherapy on Mortality from Carbapenem-Resistant Enterobacteriaceae Bacteremia：A Retrospective Observational Study from a Chinese Network [J]. Antimicrob Agents Chemother，2018，63（1）：e01511-18.
[25] Ni W，Han Y，Liu J，et al. Tigecycline Treatment for Carbapenem-Resistant Enterobacteriaceae Infections：A Systematic Review and Meta-Analysis [J]. Medicine （Baltimore），2016，95（11）：e3126.
[26] Tumbarello M，Trecarichi EM，De Rosa FG，et al. Infections caused by KPC-producing Klebsiella pneumoniae：differences in therapy and mortality in a multicentre study [J]. J Antimicrob Chemother，2015，70（7）：2133-2143. |
|
|
|
